Ceapro (CZO.V) Stock Price
Ceapro Price
Revenue has compounded at 8.8% per year over the past 19 years to 9.63 M CAD. Earnings per share have grown at 16.6% per year over the last 12 years. Ceapro's net margin stands at -48.9%, down from -8.8% several years earlier.
Ceapro stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Ceapro over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ceapro stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ceapro's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Ceapro Price |
|---|
Ceapro Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Ceapro Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM CAD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM CAD |
| EBITM CAD |
| EBIT MARGIN% |
| NET INCOMEM CAD |
| NET INCOME GROWTH% |
| SHARESM |
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 8.00 | 10.00 | 13.00 | 12.00 | 11.00 | 12.00 | 15.00 | 17.00 | 18.00 | 9.00 | 24.00 |
| – | 25.00 | – | – | 20.00 | 33.33 | 25.00 | 30.00 | -7.69 | -8.33 | 9.09 | 25.00 | 13.33 | 5.88 | -50.00 | 166.67 |
| 50.00 | 40.00 | 60.00 | 40.00 | 50.00 | 50.00 | 70.00 | 69.23 | 58.33 | 54.55 | 41.67 | 46.67 | 52.94 | 61.11 | 33.33 | 33.33 |
| 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 4.00 | 7.00 | 9.00 | 7.00 | 6.00 | 5.00 | 7.00 | 9.00 | 11.00 | 3.00 | 8.00 |
| – | – | – | – | – | 1.00 | 3.00 | 5.00 | 2.00 | – | – | 2.00 | 2.00 | 5.00 | -6.00 | – |
| – | – | – | – | – | 12.50 | 30.00 | 38.46 | 16.67 | – | – | 13.33 | 11.76 | 27.78 | -66.67 | – |
| – | – | – | – | – | 1.00 | 4.00 | 3.00 | – | – | -1.00 | 1.00 | 3.00 | 4.00 | -4.00 | – |
| – | – | – | – | – | – | 300.00 | -25.00 | – | – | – | -200.00 | 200.00 | 33.33 | -200.00 | – |
| 51.71 | 56.51 | 60.28 | 60.28 | 62.02 | 61.54 | 65.68 | 76.83 | 75.71 | 77.05 | 77.88 | 78.71 | 78.33 | 78.23 | 78.29 | 78.29 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Ceapro generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ceapro retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ceapro's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Ceapro has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ceapro's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Ceapro stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Ceapro Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Ceapro business model & stock analysis
Ceapro SWOT Analysis
Strengths
Ceapro Inc has a strong research and development team that continually innovates and creates new products, giving the company a competitive edge in the market.
The company has a diverse product portfolio, offering a wide range of high-quality natural ingredients for various industries, including pharmaceuticals, cosmetics, and nutraceuticals.
Ceapro Inc has established strong relationships with key suppliers and distributors, allowing them to maintain a consistent supply chain and reach customers globally.
The company has a solid financial position, with steady revenue growth and profitability, enabling them to invest in research and development activities and expand their operations.
Weaknesses
Ceapro Inc relies heavily on a limited number of major customers, which poses a risk to the company if it were to lose any of these key accounts.
The company's global presence is relatively small compared to some competitors, limiting their market reach and potential for growth.
Ceapro Inc faces the challenge of maintaining consistent product quality and ensuring efficient manufacturing processes to meet market demand.
Opportunities
The rise in demand for natural and sustainable ingredients in various industries provides Ceapro Inc with an opportunity to capitalize on their expertise in producing such products.
Expansion into emerging markets, such as Asia-Pacific and Latin America, can help Ceapro Inc tap into new customer segments and further grow their business.
Collaborations with academic institutions and research organizations can enhance Ceapro Inc's research capabilities and lead to the development of innovative and differentiated products.
Threats
Intense competition in the natural ingredients market can erode Ceapro Inc's market share and pricing power if they fail to differentiate themselves effectively.
Economic downturns and fluctuations in currency exchange rates may impact the company's profitability, especially if it heavily relies on export markets.
Changes in regulations and compliance requirements in the markets Ceapro Inc operates in can pose challenges and increase costs for the company.
Ceapro Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Ceapro historical P/E ratio, EBIT multiple, and P/S ratio
Ceapro annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Ceapro's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Ceapro's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Ceapro's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Ceapro shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Ceapro stock splits
Since 1997, a total of 0.2222222222222222 shares have been converted from one Ceapro share.
Ceapro Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/29/2008 | -0.01CAD | -0.01CAD | 740,949.00CAD | - | 2007 Q4 |
Ceapro shareholder structure
| % | Name |
|---|---|
2.27163% | |
0.12978% | |
0.10007% | |
0.04152% |
Ceapro Beneficial Ownership Filings (SEC 13D/G)
Ceapro Executives and Management Board
7 members · avg. age 60 · 43 % women
Mr. Gilles Gagnon
Chief Executive Officer, Director · since 2007
560,000.00 CAD
Management
Ms. Stacy Prefontaine
Chief Financial Officer
Ms. Jenene Thomas
Investor Relations
Board of Directors
Mr. Ronald Miller
Independent Chairman of the Board
Ms. Genevieve Foster
Independent Director
Dr. William Li (60)
Independent Director
Dr. Ulrich Kosciessa
Independent Director
Ceapro Supply Chain
Ceapro Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.23 | 0.67 | — | ||
| 2 | 0.74 | 0.09 | — | ||
| 3 | 0.70 | 0.73 | — | ||
| 4 | -0.46 | -0.44 | — | ||
| 5 | 0.54 | -0.07 | — |
Frequently asked questions about Ceapro
The business model of Ceapro Inc revolves around the development and commercialization of innovative natural products derived from oats and other plant sources. Ceapro specializes in the extraction and purification of active ingredients for the pharmaceutical, cosmetic, and human health markets. By leveraging its proprietary technologies, Ceapro harnesses the power of nature to create high-value products that provide sustainable and renewable solutions. With a strong focus on research and development, Ceapro aims to deliver unique and effective products for a wide range of applications, catering to the growing demand for natural and environmentally friendly alternatives.
Ceapro Inc is primarily active in the biotechnology industry.
Some major competitors of Ceapro Inc in the market include Active Organics, Ashland LLC, and Croda International.
Ceapro Inc. is a Canadian biotechnology company that specializes in developing and manufacturing innovative extracts and active ingredients derived from natural sources. Established in 1997, Ceapro has a rich history of over two decades in the biopharmaceutical industry. The company focuses on utilizing its patented technology to transform renewable resources into high-value functional products. Ceapro's expertise lies in the production of unique biopolymers, such as beta glucan, as well as other innovative solutions for human and animal health. With a commitment to sustainability and scientific excellence, Ceapro continues to thrive as a leader in the biotechnology sector.
Ceapro Inc has achieved significant milestones throughout its journey. The company successfully developed and commercialized its flagship product, Avenanthramides, which has gained recognition for its numerous health benefits. Additionally, Ceapro Inc has built a strong research and development platform, leading to the creation of innovative products derived from natural sources. The company has also collaborated with renowned academic institutions and established partnerships with leading players in the industry, enhancing its global presence. With a dedicated focus on sustainability and continuous growth, Ceapro Inc remains committed to delivering high-quality, nature-based solutions to improve the health and well-being of consumers.
Ceapro Inc is primarily present in Canada and the United States.
Ceapro Inc represents values of excellence, innovation, and sustainability. As a biotechnology company, Ceapro is dedicated to developing and commercializing active ingredients derived from natural resources for personal care, cosmetics, and pharmaceutical industries. The corporate philosophy of Ceapro emphasizes a commitment to cutting-edge research, high-quality products, and environmental responsibility. By combining advanced technology with a deep understanding of natural materials, Ceapro aims to provide effective and sustainable solutions to its clients. With its focus on innovation and dedication to eco-friendly practices, Ceapro Inc stands as a leading player in the biotechnology industry.
9 analysts currently rate the Ceapro stock: 8 recommend buying, 1 holding and 0 selling.
The Ceapro share (CZO.V) is listed on 2 stock exchanges, including: Toronto (CZO.V).
Ceapro Inc is a Canadian company specialized in the development and manufacturing of natural health and beauty products from plant and marine sources. The company is headquartered in Edmonton, Alberta, and has state-of-the-art production facilities, research and development departments, as well as sales and marketing teams in North America, Europe, and Asia. Ceapro offers a wide range of products that are highly regarded worldwide for their high quality and effectiveness. These include products from five different business units: 1. Health and Wellness: This business unit includes products such as Beta-Glucan, a natural immune stimulant used mainly in the pharmaceutical and food industry. Ceapro also produces Chitosan, a fiber derived from crabs and shrimps, used in wound healing, cosmetics, and dietary supplements. 2. Cosmeceuticals: Under this unit, Ceapro offers skincare products based on natural ingredients such as Beta-Glucan and Avenanthramid. The company provides an anti-aging product line, such as HyaClear, which is based on Hyaluronic Acid. 3. Functional Food: Ceapro offers natural food additives under this unit that provide health benefits, such as Beta-Glucan or plant fibers that support digestion. 4. Veterinary Health: Ceapro also produces a range of veterinary products, including Beta-Glucan-based products to strengthen pets' immune systems and Chitosan-based wound care products. 5. Active Ingredients: Under this business unit, Ceapro supplies natural active ingredients to the pharmaceutical and cosmetics industries, which can be used in prescription products, over-the-counter medications, and cosmetics. Ceapro employs an integrated approach that extends from research and development to the production process to ensure high quality and effectiveness of its products. The company relies on unique and patented processes to extract active ingredients from plant and marine sources and consistently invests in research and development to develop innovative products that meet market needs. The company is led by an experienced management team composed of seasoned scientists and business professionals who share Ceapro's vision of improving people's lives by offering natural products of the highest quality. To effectively market its products, Ceapro relies on a global distribution strategy that includes a comprehensive presence in North America, Europe, and Asia. The company maintains strong partnerships with several companies in various industries, including animal health, food, pharmaceutical, and cosmetics industries. Conclusion Ceapro Inc is a leading company in the development and production of natural health and beauty products from plant and marine sources. The company specializes in five business units that encompass a wide range of products, from food additives to animal health products. Ceapro employs an integrated research and development strategy to develop innovative products that meet market needs. The company has a broad global distribution strategy and is dedicated to offering natural products of the highest quality to improve people's lives.
The revenue cannot currently be calculated for Ceapro.
The profit cannot currently be calculated for Ceapro.
The P/E ratio cannot be calculated for Ceapro at the moment.
The P/S cannot be calculated for Ceapro currently.
The Eulerpool Quality Score for Ceapro is 1/10.
The ISIN of Ceapro is CA1499071076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ceapro is 931278. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ceapro is CZO.V. The ticker symbol is used to trade Ceapro shares on the stock exchange.
Ceapro is assigned to the 'Commodities' sector.
The dividends of Ceapro are distributed in CAD.
Ceapro stock
Ceapro Peer Group
Ceapro Ticker
Ceapro FIGI
All fundamentals and in-depth analysis of Ceapro
Our stock analysis for Ceapro stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ceapro. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.